Young Dong Yu1, Moon Hyung Kang1, Chang Il Choi1, Hyun Soo Shin2, Jong Jin Oh3, Dong Soo Park4. 1. Department of Urology, CHA Bundang Hospital, CHA University College of Medicine, 59 Yatap-ro, Bundang-gu, Seongnam, 463-712, Korea. 2. Department of Radiation Oncology, CHA Bundang Medical Center, CHA University, Seongnam, Korea. 3. Department of Urology, Seoul National University Bundang Hospital, Seongnam, Korea. 4. Department of Urology, CHA Bundang Hospital, CHA University College of Medicine, 59 Yatap-ro, Bundang-gu, Seongnam, 463-712, Korea. dsparkmd@cha.ac.kr.
Abstract
PURPOSE: To investigate the efficacy of tamsulosin monotherapy and tamsulosin with low-dose sildenafil combination therapy on lower urinary tract symptoms (LUTS) following low-dose-rate (LDR) brachytherapy in early prostate cancer patients. METHODS: From March 2008 to June 2014, of the 212 prostate cancer patients with a Gleason score ≤7 who receivedLDR brachytherapy, 80 patients with a prostate volume ≤35 g and progressed LUTS following implantation were selected. All 80 patients took tamsulosin 0.4-mg monotherapy until 1 month after implantation. Then, the patients were divided into two groups; 45 patients received tamsulosin 0.4-mg monotherapy, and 35 patients received tamsulosin 0.4-mg plus sildenafil 25-mg combination therapy due to erectile dysfunction. LUTS were compared between the two groups using the International Prostate Symptom Score (IPSS), the mean maximum flow rate (Q max) and the pre-implantation post-voiding residual (PVR) volume at 1 and 3 months after implantation. RESULTS: The pre-implantation total IPSS, Q max and PVR for the monotherapy and combination therapy groups were 14.0 ± 6.7, 14.3 ± 3.2 ml/s and 36.3 ± 16.7 ml and 15.3 ± 5.6, 13.7 ± 4.5 ml/s and 39.0 ± 23.4 ml, respectively. At 1 month post-implantation, both groups showed increases in total IPSS and PVR, but no statistically significant differences were observed (P = 0.078, P = 0.23). At 3 months post-implantation, the combination therapy group showed a greater decrease in total IPSS compared with the monotherapy group (P = 0.035), but there were no statistically significant differences in the Q max and PVR between the two groups. CONCLUSION:Tamsulosin plus low-dose sildenafil combination therapy is a beneficial treatment for post-implantation progression of LUTS.
RCT Entities:
PURPOSE: To investigate the efficacy of tamsulosin monotherapy and tamsulosin with low-dose sildenafil combination therapy on lower urinary tract symptoms (LUTS) following low-dose-rate (LDR) brachytherapy in early prostate cancerpatients. METHODS: From March 2008 to June 2014, of the 212 prostate cancerpatients with a Gleason score ≤7 who received LDR brachytherapy, 80 patients with a prostate volume ≤35 g and progressed LUTS following implantation were selected. All 80 patients took tamsulosin 0.4-mg monotherapy until 1 month after implantation. Then, the patients were divided into two groups; 45 patients received tamsulosin 0.4-mg monotherapy, and 35 patients received tamsulosin 0.4-mg plus sildenafil 25-mg combination therapy due to erectile dysfunction. LUTS were compared between the two groups using the International Prostate Symptom Score (IPSS), the mean maximum flow rate (Q max) and the pre-implantation post-voiding residual (PVR) volume at 1 and 3 months after implantation. RESULTS: The pre-implantation total IPSS, Q max and PVR for the monotherapy and combination therapy groups were 14.0 ± 6.7, 14.3 ± 3.2 ml/s and 36.3 ± 16.7 ml and 15.3 ± 5.6, 13.7 ± 4.5 ml/s and 39.0 ± 23.4 ml, respectively. At 1 month post-implantation, both groups showed increases in total IPSS and PVR, but no statistically significant differences were observed (P = 0.078, P = 0.23). At 3 months post-implantation, the combination therapy group showed a greater decrease in total IPSS compared with the monotherapy group (P = 0.035), but there were no statistically significant differences in the Q max and PVR between the two groups. CONCLUSION:Tamsulosin plus low-dose sildenafil combination therapy is a beneficial treatment for post-implantation progression of LUTS.
Authors: Gregory S Merrick; Wayne M Butler; Kent E Wallner; Robert W Galbreath; Zachariah A Allen; Sarah Gutman; Jonathan Lief Journal: Cancer J Date: 2007 Mar-Apr Impact factor: 3.360
Authors: Raymond Rosen; Jens Altwein; Peter Boyle; Roger S Kirby; B Lukacs; Eric Meuleman; Michael P O'Leary; Paolo Puppo; Chris Robertson; Francois Giuliano Journal: Eur Urol Date: 2003-12 Impact factor: 20.096
Authors: Andrew C Meltzer; Pamela Katzen Burrows; Allan B Wolfson; Judd E Hollander; Michael Kurz; Ziya Kirkali; John W Kusek; Patrick Mufarrij; Stephen V Jackman; Jeremy Brown Journal: JAMA Intern Med Date: 2018-08-01 Impact factor: 21.873
Authors: Tae Heon Kim; Jong Nyeong Kim; Young Dong Yu; Seung Ryeol Lee; Young Kwon Hong; Hyun Soo Shin; Dong Soo Park Journal: J Contemp Brachytherapy Date: 2020-10-30
Authors: Marian Cruz-Burgos; Alberto Losada-Garcia; Carlos D Cruz-Hernández; Sergio A Cortés-Ramírez; Ignacio Camacho-Arroyo; Vanessa Gonzalez-Covarrubias; Miguel Morales-Pacheco; Samantha I Trujillo-Bornios; Mauricio Rodríguez-Dorantes Journal: Front Oncol Date: 2021-02-26 Impact factor: 6.244
Authors: Belinda Li; Eric J Kirshenbaum; Robert H Blackwell; William S Gange; Jennifer Saluk; Matthew A C Zapf; Anai N Kothari; Robert C Flanigan; Gopal N Gupta Journal: Prostate Int Date: 2018-03-14